<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">IFX-1 is a monoclonal antibody designed to induce an anti-inflammatory response by blocking the biological activity of human complement factor C5a. One trial (NCT04333420) is currently being held in the Netherlands to test its efficacy in patients with severe COVID-19, with preliminary results expected by December 31, 2020. It will soon be studied in a Phase 3 trial on patients with severe COVID-19 induced pneumonia after promising results in the earlier phases 
 <xref rid="b0360" ref-type="bibr">[72]</xref>.
</p>
